
Merck's Keytruda Gains EU and US Approvals for New Formulations and Indications
Merck received positive EU CHMP opinions for its cancer drug KEYTRUDA, including approval for subcutaneous administration and a new indication for earlier-stage head and neck cancer, potentially expanding treatment options in Europe.




